Symbols

ARCT

Arcturus Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ARCT

Arcturus Therapeutics Holdings Inc.

A company that developing lipid nanoparticle siRNA drug delivery systems for the orphan disease market

Industry

Pharmaceutical

Established Date

02/07/2008

Listing Date

05/22/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

106

Fiscal Year Ends

12-31

Website

www.arcturusrx.com

Security Type

Common stock

Office address

10285 Science Center Drive, San Diego, California 92121

Business

Introduction

Arcturus Therapeutics Holdings Inc., incorporated and commenced operations in Israel on February 7, 2008, and re-incorporated in Delaware. The company is a messenger ribonucleic acid drug company focused on developing therapies for rare diseases of the liver and respiratory tract. Its platform technologies include a proprietary self-replicating mRNA and lipid nanoparticle delivery system, supporting a pipeline of drug candidates for diseases such as ornithine carbamyltransferase deficiency and cystic fibrosis, and a co-developed COVID - 19 vaccine.

Company Financials

EPS

ARCT has released its 2025 Q4 earnings. EPS was reported at -1.03, versus the expected 4.28, missing expectations. The chart below visualizes how ARCT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ARCT has released its 2025 Q4 earnings report, with revenue of 7.20M, reflecting a YoY change of -68.39%, and net profit of -29.08M, showing a YoY change of 3.09%. The Sankey diagram below clearly presents ARCT's revenue sources and cost distribution.